Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout

Esperion strikes Japan deal for 'goldilocks' cholestrol drug, bags $60M cash as pandemic forces virtual US rollout

Source: 
Endpoints
snippet: 

Esperion has forged its first regional deal for Nexletol and Nexlizet since winning US and EU approvals for the cholesterol fighting drugs, bagging $60 million upfront while securing a pharma partner in Japan.